Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hologic Sees Past Trex Net Loss, Inks $55 Mil. Purchase Deal

This article was originally published in The Gray Sheet

Executive Summary

Hologic will evaluate Trex Medical's premarket approval application for the firm's full-field digital mammography system before making a submission to FDA, the company said following its announcement of a definitive agreement to acquire the Thermo Electron subsidiary for $55 mil. on Aug. 15.

You may also be interested in...



Digital Mammography Approval Times Accelerate; Adoption May Take Longer

Swift FDA approval of PMAs for full-field digital mammography systems, such as Hologic's LORAD, is anticipated following rapid turnaround of the Fischer SenoScan system approval.

Digital Mammography Approval Times Accelerate; Adoption May Take Longer

Swift FDA approval of PMAs for full-field digital mammography systems, such as Hologic's LORAD, is anticipated following rapid turnaround of the Fischer SenoScan system approval.

Thoratec Finds HeartMate In Thermo Cardiosystems; Deal Valued At $570 Mil.

Acquisition of Thermo Cardiosystems by Thoratec Laboratories will broaden Thoratec's heart-assist device R&D pipeline to include an alternative-to-transplant indication, provide expanded selling opportunities at 80 U.S. heart failure treatment centers, and generate combined revenues of $130-140 mil. in fiscal 2001.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013758

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel